VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (1328)	6/21/1997 12:11:00 AM
From: Vector1	of 9719

PB, I have not seen the Biocentury article. I am a recent subscriber (yes I agreed to pay the full dues but I have become a biotech addict). When I get back from vacation I will request the back copy. I have heard from one person I respect that there are some mylotoxicity problems with Y2B8. Because of the nature of the compound more of the radiation is absorbed by the tissues. Does this make sense to you. Richard or anyone else have a view. I am giving serious consideration to IDPH calls. By all rights they should get approval C2B8 and I think it will catch on quick. Frankly the more I think about it there will be room for both IDPH and Coulter to make money for their shareholders. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next